CARLSBAD, Calif., Sept. 18, 2024 /PRNewswire/ -- The pioneering health and wellness brand formerly known as Neurohacker Collective, has recently completed…
Investment to bolster leading multi-site clinical trial organization to further scale across therapeutic areas and geographies APEX, N.C. and SAN…
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50…
The first-in-human Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of ENX-104 in healthy volunteers…
Detailing the intricate process of early embryogenesis, this year's winning video provides insights into fundamental biological processes with far-reaching implications.…
ORLANDO, Fla., Sept. 16, 2024 /PRNewswire/ -- Anervea.ai, a global leader in AI-powered commercialization solutions for the Pharmaceutical, Life Sciences,…
SAN FRANCISCO, Sept. 16, 2024 /PRNewswire/ -- Darmiyan, Inc., a pioneer in brain technology, is proud to announce the launch…
Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the primary endpoints…
RIYADH, Saudi Arabia, Sept. 15, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is cementing its…
Marks first EMA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and…
